Key New Zealand skin cancer primary prevention documents and recommendations
5 February 2022This section provides links to key New Zealand skin cancer primary prevention documents and recommendations.
The economics of skin cancer prevention with implications for Australia and New Zealand
17 January 2022According to this recent study, the majority of skin cancers are avoidable and curable, yet cost the Australian health economy A$1.7 billion each year. Therefore primary prevention of skin cancers must remain high on the public health agenda. This overview presents the current ‘state of play’ of the economics of skin cancer prevention.
Factors influencing participants' engagement with an interactive text-message intervention to improve sun protection behaviors
21 December 2021This study evaluated the effect of different combinations of personalized and two-way interactive messages on participant engagement with a theory-based skin cancer prevention intervention. Results suggest enhanced engagement with constant or decreasing message frequency compared to increasing frequency.
Use of video “Dear 16-Year-Old Me,” as melanoma education tool results in participant health behaviour changes
21 December 2021Viewing “Dear 16-Year-Old Me,” resulted in reported participant changes in intention to tan outdoors and participate in skin surveillance. In the age of viral videos and readily accessible health information via the internet, continued investigation of video media on patient health behaviors should be pursued.
Metastatic acral melanoma treatment outcomes: systematic review and meta-analysis
21 December 2021This study provides estimates of treatment response for metastatic acral melanoma, demonstrating low activity across a breadth of approved drug therapies, including anti-PD-1, the most active therapy in melanoma to date.
Exploring outcomes of rechallenge and retreatment with immune checkpoint inhibitors (ICIs) in melanoma patients
21 December 2021According to this recent study, retreatment, rechallenge and escalation are available options for patients with melanoma who relapse in the adjuvant or advanced setting.
Multiparametric MRI potential for early detection of successful response to immune checkpoint inhibitors in metastatic melanoma
21 December 2021According to this recent study, multiparametric MRI demonstrated potential for early detection of successful response to immune checkpoint inhibitors in metastatic melanoma.
Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma
21 December 2021Analysis of this recent study indicates genetic correlation between traits can be leveraged to identify new risk genes for cutaneous melanoma.
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with inflamed tumor microenvironment
21 December 2021According to this recent study, the TIGIT/CD155 axis mediates resistance to immune checkpoint inhibitors in patients with melanoma with an inflamed tumor microenvironment, promoting the development of TIGIT blockade therapies in such patients with cancer.
Dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma
21 December 2021According to this recent study, the new method of dual-energy CT-specific radiomic analysis provides a significant additive value over single-energy CT radiomics approaches for response prediction in patients with metastatic melanoma preceding immunotherapy, especially on a lesion-based level.